# Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

> **NCT02134717** · NA · TERMINATED · sponsor: **Kevin F. Gibson** · enrollment: 3 (actual)

## Conditions studied

- Sarcoidosis

## Interventions

- **DRUG:** all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
- **PROCEDURE:** Bronchoscopy with bronchoalveolar lavage
- **PROCEDURE:** venipunctures
- **PROCEDURE:** Skin biopsy

## Key facts

- **NCT ID:** NCT02134717
- **Lead sponsor:** Kevin F. Gibson
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2025-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134717, "Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02134717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*